ClinicalTrials.gg
CompletedNCT00035152Updated Sep 19, 2016

Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer

A Phase 3 interventional study of Paclitaxel and carboplatin in Carcinoma, Non-Small-Cell Lung, sponsored by Bristol-Myers Squibb. Completed at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-19.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 222 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung — 17 open to participants now, 25 under way, 6 of them phase 3. Paclitaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
19th of 204
444 · median 51
Started
2000
with 12 others
Phase 3
40 of 222
5 open now
Registered
48th of 222
by date
Lead sponsor
4 of 222
Bristol-Myers Squibb

Among the 222 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment of the 204 interventional ones that give a count, is one of 13 that started in 2000, is one of 40 in phase 3, and was the 48th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

17 of the 222 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 222 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma.

This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly.

The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation of non-small cell bronchogenic carcinoma (epidermoid, squamous, adeno, large cell anaplastic carcinoma, but no small cell or carcinoid) must be or cytologically confirmed.
  • No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological response modifiers
  • No previous irradiation to the only area of .

Exclusion criteria

Exclusion Criteria:

  • Past or current history of neoplasm other than the entry diagnosis. Exceptions are curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other cancers treated by surgery or radiation with a disease free survival longer than 5 years.
  • Patients who have undergone surgery less than 3 weeks prior to enrollment.
  • History of serious cardiac disease not adequately controlled.
  • Patients with serious active infections or other serious underlying medical condition.
  • Uncontrolled diabetes mellitis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
444 participants

Interventions

06

Study locations

56 sites
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Little Rock Hematology/Oncology Associates
    Little Rock, Arkansas 72205, United States
  • Highlands Oncology Group
    Springdale, Arkansas 72764, United States
  • Medical Oncology Care Associates
    Orange, California 92868, United States
  • Naval Medical Center
    San Diego, California 92134, United States
  • Danbury Hospital/Praxair Cancer Center
    Danbury, Connecticut 06810, United States
  • Walter Reed Army Hospital
    Washington, District of Columbia 20307, United States
  • Washington VA Medical Center
    Washington, District of Columbia 20422, United States
  • Good Samaritan Medical Center
    West Palm Beach, Florida 33401, United States
  • Wellstar Cobb Hospital
    Austell, Georgia 30060, United States
  • Joliet Oncology/Hematology Associates,Ltd.
    Joliet, Illinois 60435, United States
  • Mid Illinois Hematology and Oncology Associates, Ltd.
    Normal, Illinois 61761, United States
  • West Suburban Center for Cancer Care
    River Forest, Illinois 60305, United States
  • Community Cancer Care, Inc.
    Indianapolis, Indiana 46202, United States
  • Associated Physicians & Surgeons Clinic, LLC
    Terre Haute, Indiana 47804, United States
  • Mercy Cancer Center
    Mason City, Iowa 50401, United States
  • Siouxland Hematology/Oncology Associates
    Sioux City, Iowa 51101, United States
  • Jewish Medical Plaza
    Louisville, Kentucky 40202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Louisiana Oncology Associates
    Lafayette, Louisiana 70506, United States
  • Louisiana State University Health Sciences Center
    Shreveport, Louisiana 71130, United States
  • Maine General Medical Center
    Waterville, Maine 04901, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Hematology and Oncology Associates of Southern Michigan,P.C
    Jackson, Michigan 49201, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Fairview-University Medical Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Metro Minnesota CCOP
    St. Louis Park, Minnesota 55416, United States
  • Ellis Fischel Cancer Center
    Columbia, Missouri 65203, United States
  • Creighton University Cancer Center
    Omaha, Nebraska 68131, United States
  • The Center for Cancer and Hematologic Disease
    Cherry Hill, New Jersey 08003, United States
  • Hematology-Oncology of Central New Jersey
    Red Bank, New Jersey 07701, United States
  • Community Medical Center
    Toms River, New Jersey 08755, United States
  • New Mexico Oncology Hematology Consultants
    Albuquerque, New Mexico 87109, United States
  • Advanced Oncology Associates
    Armonk, New York 10504, United States
  • Brooklyn VA
    Brooklyn, New York 11209, United States
  • Maimonides Medical Center
    Brooklyn, New York 11209, United States
  • Clifton Springs Hospital and Clinic
    Clifton Springs, New York 14432, United States
  • Goshen Medical Associates
    Goshen, New York 10924, United States
  • New York Oncology-Hematology,P.C./Capital District Hematology, Oncology Associates
    Latham, New York 12110, United States
  • Hematology/Oncology of Rockland
    New York, New York, United States
  • Upstate New York Cancer R & E
    Rochester, New York 14623, United States
  • Raleigh Hematology Associates, Wake Practice
    Cary, North Carolina 27609, United States
  • Quadrangle Medical Specialists, Southern Oncology Research
    Greenville, North Carolina 27834, United States
  • Mid Dakota Clinic
    Bismarck, North Dakota 58501, United States
  • Columbus CCOP
    Columbus, Ohio 43206, United States
  • Central Pennsylvania Hematology & Medical Oncology Associates, P.C.
    Lemoyne, Pennsylvania 17043, United States
  • Albert Einstein Healthcare Network
    Philadelphia, Pennsylvania 19141, United States
  • University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15213, United States
  • Guthrie Clinic Ltd
    Sayre, Pennsylvania 18840, United States
  • Boston Cancer Group, PLC
    Memphis, Tennessee 38104, United States
  • Don & Sybil Harrington Cancer Center
    Amarillo, Texas 79106, United States
  • Brackenridge Hospital
    Austin, Texas 78701, United States
  • Southwest Regional Cancer Center
    Austin, Texas 78705, United States
  • Southwest Cancer Center
    Lubbock, Texas 79415, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Madigan Army Medical Center
    Tacoma, Washington 98431, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2000 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2002
First posted
May 3, 2002
Start
Jun 2000
Completion
Dec 2004
Last update
Sep 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Sep 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00035152
First posted
May 3, 2002
Start date
Jun 2000
Completion
Dec 2004
Last update
Sep 19, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Carboplatin

Start the discussion